Phase 2 study finds intranasal esketamine effective in treatment ‐resistant depression

Patients with treatment‐resistant depression who received intranasal esketamine as adjunctive therapy with an antidepressant experienced greater symptom improvement than patients receiving adjunctive placebo, a multiphase study with 67 participants has found. The antidepressant effect seen in the study was dose‐related, and adverse events led to study discontinuation in only a small number of participants. Study results were published online Dec. 27, 2017, in JAMA Psychiatry.

Source: The Brown University Psychopharmacology Update - March 9, 2018 Category: Psychiatry Tags: Depression Treatment Source Type: research